These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31040267)

  • 1. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis.
    Liang M; Ma Q; Ding N; Luo F; Bai Y; Kang F; Gong X; Dong R; Dai J; Dai Q; Dou C; Dong S
    Cell Death Dis; 2019 Apr; 10(5):353. PubMed ID: 31040267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
    Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
    Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
    [No Abstract]   [Full Text] [Related]  

  • 3. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling.
    Sung B; Oyajobi B; Aggarwal BB
    Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
    Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
    Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
    Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
    Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
    Liu Y; Zhang RX; Yuan W; Chen HQ; Tian DD; Li H; Jiang X; Deng ZL; Wang Y
    Cell Physiol Biochem; 2018; 45(5):1759-1771. PubMed ID: 29495003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells.
    McCoy EM; Hong H; Pruitt HC; Feng X
    BMC Cancer; 2013 Jan; 13():16. PubMed ID: 23311882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
    Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
    Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germacrone alleviates breast cancer-associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF-κB signaling pathways.
    Lin Z; Yang Y; Liu T; Wu Z; Zhang X; Yang J
    Phytother Res; 2024 Jun; 38(6):2860-2874. PubMed ID: 38558446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
    Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
    Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
    Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
    PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epiberberine inhibits bone metastatic breast cancer-induced osteolysis.
    Wei C; Shi M; Wang Z; Lan W; Feng N; Zhang F; Liu J; Lang JY; Lin W; Ma W
    J Ethnopharmacol; 2024 Jun; 327():118039. PubMed ID: 38479545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro.
    Murakami K; Kobayashi Y; Uehara S; Suzuki T; Koide M; Yamashita T; Nakamura M; Takahashi N; Kato H; Udagawa N; Nakamura Y
    PLoS One; 2017; 12(7):e0181126. PubMed ID: 28708884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
    Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
    Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system].
    Sheng L; Wu CY; Chen XF
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 May; 31(5):684-9. PubMed ID: 21812275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SREBP-2 aggravates breast cancer associated osteolysis by promoting osteoclastogenesis and breast cancer metastasis.
    Jie Z; Xie Z; Xu W; Zhao X; Jin G; Sun X; Huang B; Tang P; Wang G; Shen S; Qin A; Fan S
    Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):115-125. PubMed ID: 30394316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
    Nannuru KC; Futakuchi M; Varney ML; Vincent TM; Marcusson EG; Singh RK
    Cancer Res; 2010 May; 70(9):3494-504. PubMed ID: 20406980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
    Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
    Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis
    Yang J; Tang R; Yi J; Chen Y; Li X; Yu T; Fei J
    FASEB J; 2019 Jun; 33(6):7261-7273. PubMed ID: 30857415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.